Bringing you the latest research in Drug Discovery In New Modalities, Integration Of DEL, Covalent Inhibitors, Protein Degradation Technologies, Computational Drug Design & Automation Strategies and more, through a range of Speaker Interviews, Industry Insights, and Expert Opinions.
Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry at Biogen, leads a discussion group on what the revolutionary machine learning technology means for drug design.
There are innumerable possible compounds in Merck KGaA’s virtual library, so finding drug candidates is only possible with the help of computational methods.
Artificial intelligence and machine learning could be an invention comparable to electricity, so what does the future hold for its use in drug discovery?
In drug discovery, structural knowledge of a target enables structure-based design approaches and thereby reduces the time and labor required to develop a therapy.
Reaxys prediction retrosynthesis predicts the synthesis route for BMS-986299 targeting NLRP3 inflamasone, a protein that can stimulate the immune system’s ability to recognize and fight tumor cells